These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 8754091)

  • 21. Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms.
    Fidelholtz J; Smith W; Rawls J; Shi Y; Zack A; Rüegg P; Lefkowitz M
    Am J Gastroenterol; 2002 May; 97(5):1176-81. PubMed ID: 12014724
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment of irritable bowel syndrome with dicetelium and spasmomen].
    Nedogoda SV; Parshev VV
    Klin Med (Mosk); 2000; 78(10):42-6. PubMed ID: 11220900
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New drugs to treat irritable bowel syndrome being tested.
    Mayo Clin Health Lett; 2000 Mar; 18(3):4. PubMed ID: 10734837
    [No Abstract]   [Full Text] [Related]  

  • 24. A trial of trimebutine in spastic colon.
    Lüttecke K
    J Int Med Res; 1978; 6(2):86-8. PubMed ID: 344090
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alosetron for irritable bowel syndrome. Senior vice president of GlaxoSmithKline responds.
    Palmer JB
    BMJ; 2003 Jan; 326(7379):51. PubMed ID: 12511473
    [No Abstract]   [Full Text] [Related]  

  • 26. Alosetron for irritable bowel syndrome. Risks of using alosetron are still unknown.
    Palmer RH
    BMJ; 2003 Jan; 326(7379):51. PubMed ID: 12518769
    [No Abstract]   [Full Text] [Related]  

  • 27. Irritable bowel syndrome. A poorly understood disorder.
    Lewis C
    FDA Consum; 2001; 35(4):30-6. PubMed ID: 11692885
    [No Abstract]   [Full Text] [Related]  

  • 28. [Irritable bowel syndrome: current views on its pathogenesis, diagnosis and treatment].
    Sheptulin AA
    Klin Med (Mosk); 1997; 75(9):26-9. PubMed ID: 9432536
    [No Abstract]   [Full Text] [Related]  

  • 29. [Irritable colon].
    Meier R; Meyer M; Degen L
    Ther Umsch; 1997 Nov; 54(11):654-60. PubMed ID: 9454369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A clinical trial of trimebutine (Mebutin) in spastic colon.
    Moshal MG; Herron M
    J Int Med Res; 1979; 7(3):231-4. PubMed ID: 456734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Comparative study on irritable bowel syndrome treated with acupuncture and western medicine].
    Shi ZM; Zhu YS; Wang QX; Lei MN
    Zhongguo Zhen Jiu; 2011 Jul; 31(7):607-9. PubMed ID: 21823282
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Delayed reaction urticaria due to trimebutine.
    Martin-Garcia C; Martinez-Borque N; Martinez-Bohigas D; Torrecillas-Toro M; Palomeque-Rodrìguez MT
    Allergy; 2004 Jul; 59(7):789-90. PubMed ID: 15180771
    [No Abstract]   [Full Text] [Related]  

  • 33. Tegaserod: a novel, selective 5-HT4 receptor partial agonist for irritable bowel syndrome.
    Beglinger C
    Int J Clin Pract; 2002; 56(1):47-51. PubMed ID: 11831835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects.
    Morganroth J; Rüegg PC; Dunger-Baldauf C; Appel-Dingemanse S; Bliesath H; Lefkowitz M
    Am J Gastroenterol; 2002 Sep; 97(9):2321-7. PubMed ID: 12358251
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A systematic review of tegaserod for the treatment of irritable bowel syndrome.
    Bergmann K
    J Clin Pharm Ther; 2003 Apr; 28(2):151-3; author reply 153. PubMed ID: 12713613
    [No Abstract]   [Full Text] [Related]  

  • 36. [Diets in irritable bowel syndrome--what do they really achieve? Please no culinary sadism!].
    Stiefelhagen P
    MMW Fortschr Med; 2001 Nov; 143(46):18. PubMed ID: 11759593
    [No Abstract]   [Full Text] [Related]  

  • 37. Irritable bowel syndrome.
    Sharma MP; Chawla Y
    J Assoc Physicians India; 1983 Mar; 31(3):163-6. PubMed ID: 6619085
    [No Abstract]   [Full Text] [Related]  

  • 38. Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome.
    Olden K; DeGarmo RG; Jhingran P; Bagby B; Decker C; Markowitz M; Carter E; Bobbitt W; Dahdul A; DeCastro E; Gringeri L; Johanson J; Levinson L; Mula G; Poleynard G; Stoltz RR; Truesdale R; Young D;
    Am J Gastroenterol; 2002 Dec; 97(12):3139-46. PubMed ID: 12492201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A new treatment of functional colopathies: Modulite].
    Chevrel B
    Med Chir Dig; 1982; 11(2):151-4. PubMed ID: 7098595
    [No Abstract]   [Full Text] [Related]  

  • 40. The treatment of irritable bowel syndrome. Two doses of mebeverine compared.
    Prout BJ
    Practitioner; 1983 Oct; 227(1384):1607-8. PubMed ID: 6356119
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.